# Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease

Study · id `cardio:ct-nct06218342` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06218342](<https://clinicaltrials.gov/study/NCT06218342>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06218342

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 156 participants.

## Technical summary

Registry record NCT06218342. Randomized; no masking; primary purpose treatment. Start 2024-02-15 (anticipated); primary completion 2025-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 156 participants (planned count; ClinicalTrials.gov record NCT06218342, source copy `cardio:ctgov-nct06218342-2024-01-23`, retrieved 2026-10-26)
- Planned start: 2024-02-15 (anticipated) (ClinicalTrials.gov record NCT06218342, source copy `cardio:ctgov-nct06218342-2024-01-23`, retrieved 2026-10-26)
- Primary completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT06218342, source copy `cardio:ctgov-nct06218342-2024-01-23`, retrieved 2026-10-26)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT06218342, source copy `cardio:ctgov-nct06218342-2024-01-23`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06218342-2024-01-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
- Condition: Type 2 Diabetes
- Condition: Non-Alcoholic Fatty Liver Disease
- Intervention (Drug): Henagliflozin
- Intervention (Other): Background medication
- Lead sponsor: Sir Run Run Shaw Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sir Run Run Shaw Hospital (`cardio:org-sir-run-run-shaw-hospital`)

## Provenance

Content hash: b71d122dba44a5ed4674a6b9ca662a444876a51efd6a48e7dc809341efa28571
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
